ArticleScientific reports2026
Curcumin-Dragon's blood-chitosan nanosuspension for dual forensic detection.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Forensic identification of latent fingerprints and bloodstains is fundamental to criminal investigations, yet conventional methods often suffer from high toxicity, low sensitivity, and substrate dependency. This study aims to address these limitations by developing a novel, biocompatible, dual-function nanosuspension formulation. The nanosuspension was synthesized using the ionic gelation method, crosslinking curcumin and Dragon's blood resin within a chitosan nanoparticle matrix using sodium tripolyphosphate (TPP). Formulation optimization was systematically performed using a Box-Behnken Design (BBD) to evaluate the impact of chitosan concentration, curcumin amount, and TPP concentration on particle properties. Forensic efficacy was assessed through fluorescence imaging and ridge detail analysis on both porous and non-porous substrates. The optimized formulation achieved highly favorable physicochemical properties, including an average particle size of 220.5 ± 5.4 nm, a stable negative zeta potential of - 31.2 ± 2.1 mV, and an encapsulation efficiency of 85.2 ± 3.1%. The nanosuspension demonstrated significant quantitative superiority in forensic application, yielding a ridge contrast ratio of 4.2 ± 0.3 compared to 2.1 ± 0.4 for standard powders. Strong fluorescence under UV illumination enabled clear visualization of fingerprints up to the 5th depletion and selective marking of bloodstains. Molecular docking confirmed a strong binding affinity of resin components with hemoglobin (8.2 kcal/mol, supporting the observed selective detection. The novel curcumin-Dragon's blood resin-chitosan nanosuspension provides a non-toxic, highly sensitive, and substrate-versatile dual-function reagent. This formulation represents a significant advancement in forensic evidence visualization with substantial potential for practical field deployment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.